TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02425397

Intervention type: GENETIC
Intervention: Genetic study
Description: study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.

Intervention type: GENETIC
Intervention: Genetic study MT-RN1
Description: study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
Study: NCT04448262

Intervention type: OTHER
Intervention: data collection
Description: collection of data about bronchial and systemic inflammation, quality of life, lung function

Intervention type: OTHER
Intervention: data collection
Description: collection of data about bronchial and systemic inflammation, quality of life, lung function
Study: NCT00531349

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: propofol general anesthesia
Description: Regional analgesia combined with sedation or a propofol general anesthesia
Study: NCT04448262

Intervention type: OTHER
Intervention: data collection
Description: collection of data about bronchial and systemic inflammation, quality of life, lung function
Study: NCT00531349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia
Study: NCT01254682

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ostenil
Description: Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard arthroscopic procedure
Description: Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
Study: NCT04060342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1275
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1275
Description: Oral
Study: NCT03586960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peak Force Measurement
Description: Force will be measured at 5,10, and 30 minutes
Study: NCT02947191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagen membrane + HUC-MSCs
Description: After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
Study: NCT01039389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
Study: NCT02308618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Immobilization
Description: After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises
Study: NCT01039389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: bid placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: bid placebo
Study: NCT02308618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
Study: NCT01278394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Solution, 5.0%
Description: Once daily application for 360 days
Study: NCT04060342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1275
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1275
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1275
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1275
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT03772925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study: NCT00145314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOX (5-fluorouracil/folinic acid/oxaliplatin)
Description: FLOX every 2nd week
Study: NCT03772925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study: NCT01597401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: 300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: 1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: 2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: 4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: 4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
Study: NCT04060342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT02692482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrocellular polyurethane foam multilayer dressing
Description: Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard care
Description: Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
Study: NCT01940328

Intervention type: DEVICE
Intervention: Transchoracic ultrasound Doppler

Intervention type: DEVICE
Intervention: Transchoracic ultrasound Doppler

Intervention type: DEVICE
Intervention: Transchoracic ultrasound Doppler
Study: NCT02164734

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Study: NCT00693680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zincas Forte
Description: 25 mgZn/day + imipramine (100-200mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo + imipramine (100-200mg/day)
Study: NCT03038659

Intervention type: DEVICE
Intervention: Penile Duplex
Description: Measuring intima media thickness
Study: NCT01597401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
Study: NCT00243100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT01431729

Intervention type: OTHER
Intervention: honey, hope,mucositis
Description: Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
Study: NCT02164734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: additional premedication in the endotracheal intubation/INSURE arm
Study: NCT03511170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELIRI
Description: Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XELIRI
Description: Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
Study: NCT03328624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Vein Thrombosis (DVT) Cuff
Description: Recovery Force's DVT II Cuff
Study: NCT03383978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-92/5.28.z
Description: Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Intravenous infusion of Ezabenlimab 240mg q 3 weeks
Study: NCT01841957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ISBCS
Description: same-day cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSBCS
Description: bilateral surgery delayed by 1-3 weeks amongst eyes
Study: NCT00115765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin Based Chemotherapy
Description: Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin Based Chemotherapy
Description: Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
Study: NCT00145314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab
Description: FLOX every 2nd week Cetuximab weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab
Description: FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly.
Study: NCT00785512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, oral administration
Study: NCT03511170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
Study: NCT02957266

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric Arc Radiotherapy
Description: Volumetric Arc Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric Arc Radiotherapy
Description: Volumetric Arc Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy
Description: Interstitial High Dose Rate Brachytherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Weekly Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly Gemcitabine

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PIK3CA
Description: PIK3CA mutations rate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PIK3CA
Description: PIK3CA mutations rate

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: KRAS
Description: KRAS mutations rate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KRAS
Description: KRAS mutations rate

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: BRAF
Description: BRAF mutations rate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRAF
Description: BRAF mutations rate

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: RRM1
Description: RRM1 mutations rate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RRM1
Description: RRM1 mutations rate
Study: NCT02429934

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: abatacept also known as Orencia also known as CTLA4-Ig
Description: 125mg injected subcutaneously weekly for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00541164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 300 mg CoQ10 twice a day for 48 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Description: 300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
Study: NCT01251978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 2 mg
Description: intravitreal injections of ranibizumab once a month, times 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg Ranibizumab
Description: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
Study: NCT04327167

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video and questionnaire
Description: Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
Study: NCT01997944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum ALbumin/interferon alpha2a
Description: 600,750 or 900 mcg dosing every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 mcg dosing every week
Study: NCT01079065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Tablets
Study: NCT01888575

Intervention type: DRUG
Intervention: Risk of low dose aspirin discontinuation
Description: PPI continuous use; No PPI usePPI
Study: NCT01876212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT05907811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocker usage
Description: The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular blocker usage
Description: The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
Study: NCT00857649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20 mg Oral Tablets Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets Once Daily
Study: NCT01723631

Intervention type: DEVICE
Group type: OTHER
Intervention: Trap Myelin Test
Study: NCT01127620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 20 mg encapsulated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: 10 mg encapsulated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: encapsulated tablets
Study: NCT03189732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Oral
Study: NCT01739920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: Povidone iodine 5% drop will be instilled into conjunctival sac.
Study: NCT00115765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Based Chemotherapy
Description: Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Based Chemotherapy
Description: Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
Study: NCT04075773

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Expressive Writing
Description: The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
Study: NCT00800865

Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker sample collection before and after dosing with cytotoxic agent(s)
Description: Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).

Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker sample collection before and after dosing with cytotoxic agent(s)
Description: A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).